VYLOY (zolbetuximab) in combination with chemotherapy is NOW AVAILABLE and approved for first-line treatment of eligible* adult patients with gastric or gastroesophageal junction adenocarcinoma in India
business

VYLOY (zolbetuximab) in combination with chemotherapy is NOW AVAILABLE and approved for first-line treatment of eligible* adult patients with gastric or gastroesophageal junction adenocarcinoma in India

– VYLOY is the first and only CLDN18.2-targeted treatment approved in the India for adult patients with HER2 negative gastric and gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive – – Central Drugs Standard Control […]